文献速递血液净化与透析

腹膜内头孢吡肟单药对比头孢唑林联合头孢他啶经验性治疗CAPD相关腹膜炎:多中心、开放标签、非劣效、随机对照试验

Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial.
PubMed 文献 · Am J Kidney Dis · 2019-07-19

该多中心开放标签非劣效随机对照试验纳入144例CAPD相关腹膜炎成人患者,比较腹膜内头孢吡肟单药(1g/d)与头孢唑林联合头孢他啶(各1g/d)持续给药。第10天腹膜炎缓解率单药组82.6%、联合组81.1%(治疗差异1.5%,90%CI -9.1%至12.1%,P=0.04),证实单药非劣效。结论认为头孢吡肟单药可作为合理的一线替代方案。

要点

  • IP头孢吡肟单药1g/d在第10天腹膜炎缓解率非劣效于头孢唑林联合头孢他啶。
  • 初始应答率、完全治愈率、复发/再感染率及全因死亡率组间无显著差异。
  • 单药方案可能降低人员负担、缩短抗生素配制时间并减少袋污染风险。

核心结论

  • 腹膜内头孢吡肟单药治疗CAPD相关腹膜炎在第10天缓解率上非劣效于头孢唑林联合头孢他啶,可作为合理的一线替代治疗。

研究设计与样本

  • 多中心、开放标签、非劣效、随机对照试验,纳入泰国8个腹膜透析中心的144例CAPD相关腹膜炎成人患者,单药组70例、联合组74例。

主要发现

  • 第10天主要应答率单药组82.6% vs 联合组81.1%,治疗差异1.5%(90%CI -9.1%至12.1%,P=0.04)。
  • 初始应答率(第5天)单药组65.7% vs 联合组60.8%,治疗差异4.9%(95%CI -10.8%至20.6%,P=0.5)。
  • 完全治愈率单药组80.0% vs 联合组80.6%,治疗差异-0.6%(95%CI -13.9%至12.8%,P=0.7)。
  • 复发性和再发性腹膜炎单药组分别为4.6%和4.6%,联合组分别为4.2%和5.6%(P=0.9和P=0.8)。
  • 全因死亡率单药组7.1% vs 联合组2.7%,治疗差异4.4%(95%CI -2.6%至11.5%),差异无统计学意义(P=0.2)。

临床怎么用

  • 对于CAPD相关腹膜炎的经验性治疗,可考虑使用腹膜内头孢吡肟1g/d持续给药作为单药方案,以简化操作并降低污染风险。

局限性

  • 研究未采用双盲设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Compared to combination therapy, intraperitoneal (IP) cefepime monotherapy for continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis may provide potential benefits in lowering staff burden, shortening time-consuming antibiotic preparation, and reducing bag contamination risk. This study sought to evaluate whether cefepime monotherapy is noninferior to combination regimens. STUDY DESIGN: Multicenter, open-label, noninferiority, randomized, controlled trial. SETTING & PARTICIPANTS: Adult incident peritoneal dialysis (PD) patients with CAPD-associated peritonitis in 8 PD centers in Thailand. INTERVENTIONS: Random assignment to either IP monotherapy of cefepime, 1g/d, or IP combination of cefazolin and ceftazidime, 1g/d, both given as continuous dosing. OUTCOMES: Primary end point: resolution of peritonitis at day 10 (primary treatment response). SECONDARY OUTCOMES: initial response (day 5), complete cure (relapse/recurrence-free response 28 days after treatment completion), relapsing/recurrent peritonitis, and death from any cause. Noninferiority would be confirmed for the primary outcome if the lower margin of the 1-sided 95% CI was not less than-10% for difference in the primary response rate. A 2-sided 90% CI was used to demonstrate the upper or lower border of the 1-sided 95% CI. RESULTS: There were 144 eligible patients with CAPD-associated peritonitis, of whom 70 and 74 patients were in the monotherapy and combination-therapy groups, respectively. Baseline demographic and clinical characteristics were not different between the groups. The primary response was 82.6% in the monotherapy group and 81.1% in the combination-therapy group (treatment difference, 1.5%; 90% CI, -9.1% to 12.1%; P=0.04). There was no significant difference in the monotherapy group compared with the combination-therapy group in terms of initial response rate (65.7% vs 60.8%; treatment difference, 4.9%; 95% CI, -10.8% to 20.6%; P=0.5) and complete cure rate (80.0% vs 80.6%; treatment difference, -0.6%; 95% CI, -13.9% to 12.8%; P=0.7). Relapsing and recurrent peritonitis occurred in 4.6% and 4.6% of the monotherapy group and 4.2% and 5.6% of the combination-therapy group (P=0.9and P=0.8, respectively). There was nominally higher all-cause mortality in the monotherapy group (7.1% vs 2.7%; treatment difference, 4.4%; 95% CI, -2.6% to 11.5%), but this difference was not statistically significant (P = 0.2). LIMITATION: Not double blind. CONCLUSIONS: IP cefepime monotherapy was noninferior to conventional combination therapy for resolution of CAPD-associated peritonitis at day 10 and may be a reasonable alternative first-line treatment. FUNDING: This study is supported by The Kidney Foundation of Thailand (R5879), Thailand; Rachadaphiseksompotch Fund (RA56/006) and Rachadaphicseksompotch Endorsement Fund (CU-GRS_61_06_30_01), Chulalongkorn University, Thailand; National Research Council of Thailand (156/2560), Thailand; and Thailand Research Foundation (IRG5780017), Thailand. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02872038.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Kitrungphaiboon T, Puapatanakul P, Chuengsaman P, et al. Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial. Am J Kidney Dis. 2019. PMID: 31331757. doi:10.1053/j.ajkd.2019.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。